INSEMPRA
25.5.2023 08:01:30 CEST | Business Wire | Press release
Insempra, a biology-powered company enabling businesses to make superior products with nature, and Fibers365, a company offering chemical-free processed fibers and substrates from annual plants, today announce that they are working together to develop and scale sustainable second-generation (2G) feedstock for the commercial production of fermentation-based ingredients.
2G feedstocks, also known as lignocellulosic feedstocks, are a key area of research and development in biotechnology as the industry is facing a growing need in the application of these in fermentation processes. Fast moving consumer good companies, for example, are demanding sustainably procured raw materials. By utilizing agricultural residues, 2G feedstock has the potential to reduce greenhouse gas emissions by replacing fossil-based and de-forestation-based ingredients and consumer products. Insempra has built a broad toolbox to use feedstocks derived from agricultural wastes and also upcoming intermediates originating from carbon capture methods.
The Fibers365 patented, modular, farm level Steam Fiber Plants allow the competitive extraction of functional cellulosic fibers, lignin and sugars from multi feedstock non-wood biomass. The sugars, currently used for the generation of biogas, can be further valorized by producing high-value products via fermentation for various industrial applications.
“By working together with Insempra, we are combining our unique 2G feedstock derived from agricultural side streams with the highly advanced fermentation technology platform needed to scale and make this sustainable feedstock accessible to broader applications.” said Stefan Radlmayr, Founder and Managing Partner of Fibers365.
One of the primary challenges with 2G feedstocks is the intrinsic material stability of lignocellulosic materials. Unlike first-generation feedstocks (e.g., those derived from beets, corn, sugarcane), which contain easily accessible sugars, lignocellulosic biomass is composed of complex structures that require pre-treatment and enzymatic hydrolysis to release the sugars. Developing efficient and cost-effective pre-treatment methods and robust enzymatic cocktails for biomass deconstruction is a key challenge in the adoption of 2G feedstocks at scale.
Insempra has successfully tested Fibers365’s 2G feedstock derived from agricultural waste streams (e.g., wheat straw) with its proprietary fermentation technology platform. Insempra is using this technology for the development of speciality lipids for application in the beauty and personal care as well as nutraceuticals and food industries. In addition to speciality lipids, Insempra is also working on the production of protein fibers and high-value functional ingredients with 2G feedstocks from agricultural waste.
“Using second-generation feedstocks in our manufacturing processes has always been one of our priorities as a biology-powered business. We are tremendously excited about the potential this technology not only has for our businesses, but for the whole industry.” said Jens Klein, CEO & Founder of Insempra.
By working together, Insempra and Fibers365 tackle the challenge of scaling and aim to maximize the potential of 2G feedstocks to support their mission to manufacture at scale in collaboration with nature, thereby contributing to a more sustainable and circular future.
About Insempra
Insempra GmbH, Munich (Germany), is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.
For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.
Led by a hand-picked team of biologists, technologists, and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.
Learn more about Insempra at insempra.bio
About Fibers365
Fibers365 GmbH, Lenningen (Germany), offers a unique, multi-feedstock biomass processing technology for annual plants to provide functional, competitive non wood biomass products such as virgin fibers for paper, packaging and textile applications as well as high value biopolymer and fertilizer side streams, produced with carbon neutral bioenergy. The products are extracted from agricultural residues such as straw by a chemical-free, regional, farm level steam explosion pulping technology, allowing easy separation of cellulosic fibers from sugars, lignin, organic acid and minerals. The use of annually regrown plants allows to compensate CO2 emissions from processing and product consumption almost instantly, by closing a yearly carbon loop.
Learn more about Fibers365 at fibers365.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
